SOURCE: Prima BioMed

August 14, 2013 07:10 ET

Prima BioMed's "CANVAS" Clinical Trial Approved to Start in Korea

SYDNEY, AUSTRALIA--(Marketwired - Aug 14, 2013) - Prima BioMed Ltd (ASX: PRR); (NASDAQ: PBMD); (ISIN: US74154B2034) ("Prima", the "Company") is pleased to announce that the Korean Ministry of Food and Drug Safety has granted approval to start the CANVAS trial at several clinical sites in Korea. The Company expects that sites in Korea will be activated and patients will be able to join the trial in the coming weeks.

CANVAS is a phase 2/3 study of CVac™ for the maintenance treatment of newly diagnosed, late- stage epithelial ovarian cancer patients who achieve remission after optimal debulking surgery and standard first line chemotherapy.

This expansion in Asia will increase the number of actively recruiting clinical sites on the trial, which has been ongoing in Australia, the United States, and a number of European countries.

Prima's CEO, Matthew Lehman said: "We are excited to have obtained Korean approval for CANVAS as the first Asian country to approve a clinical trial of CVac. We welcome several new esteemed clinical research centers to our trial. This also allows Prima to expand the geographical reach of our personalized immunocellular therapeutics platform."

Prima maintains updated information about the CANVAS trial and enrolling clinical centers on the U.S. National Institutes of Health clinical trial registry at


The CANcer VAccine Study (CANVAS) is a multi‐center, randomized, and placebo‐controlled study of CVac in mucin 1 positive, epithelial ovarian cancer patients who have undergone optimal surgery and achieve complete remission after first‐line chemotherapy. 1000 patients will be recruited to CANVAS at over 100 hospitals throughout Australia, the USA, Europe, and Asia to have 800 evaluable study patients undergo dosing. The study objectives are to ascertain if CVac, as compared to a placebo, is able to improve the time patients remain in remission before tumor progression (progression-free survival) and extend overall survival of patients. Safety parameters, quality of life impact, manufacturing quality, and additional laboratory assessments will also be investigated.

About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell- based product currently in clinical trials for ovarian cancer patients in remission and soon starting in trials for pancreatic, colorectal, and triple-negative breast cancers.

Contact Information

  • For further information please contact:

    USA Investor/Media:
    Ms. Jessica Brown
    Prima BioMed Ltd.
    +1 (919) 710-9061
    Email Contact

    Australia Investor/Media:
    Mr. James Moses
    Mandate Corporate
    +61 (0) 420 991 574
    Email Contact

    Europe Investor/Media:
    Mr. Axel Muhlhaus
    edicto GmbH
    +49 (0) 69 905505-52
    Email Contact